Multicenter, open-label single arm phase I study evaluating the safety and efficacy of combined MB-CART19.1-IBK cells and the 2nd generation BTK-inhibitor Zanubrutinib in relapsed or refractory PCNSL "Zanubrutinib and CAR T cells in R/R PCNSL: Z-CARP-Study" A prospective non-randomized multicenter phase I study

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520342-28-00

Enrollment

Registered

2026-08-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed/ refractory Primary central nervous system lymphoma (r/r PCNSL)

None listed

Sex/Gender

All

Age

18 Years to No maximum

None listed

Source: EU CTIS · Data processed: Aug 21, 2026